New: NCI-funded clinical trial search
Mednet Logo
CommunityDermatology

Does baseline facial dermatitis in a patient with AD cause hesitation when starting Dupixent due to conjunctivitis-related complications, especially when there are many available options?

Community PollStarted

Do you avoid dupixent for treatment of AD in a patient with baseline facial dermatitis due to potential for conjunctivitis-related complications?

60 physicians have voted

Join Mednetto vote and see how they answered.

4 Answers
Mednet Member
Mednet Member
Dermatology · Forefront Dermatology
Answered on

Yes, I definitely do consider this. Not necessarily because of conjunctivitis but because I’ve seen a significant number of patients with “dupilumab facial redness or reaction” with out-of-proportion head/neck flaring in AD patients. In patients with significant facial involvement at baseline, I pre...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Dermatology · Dermatologists of Central States
Answered on

I agree with Dr. @Dr. First Last completely. I definitely take it into account, but not because of conjunctivitis.

My opinion is that the literature has shown that head and neck AD is largely an overlap with seborrheic dermatitis and that IL-4 inhibition can cause an immune shift towards Th22, which...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Dermatology · UCONN
Answered on

I think baseline head and neck atopic dermatitis. At least for me, it favors JAKi's over biologics.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Dermatology · SkinBit
Answered on

Thank you, I didn't recognize the pervasiveness of this adverse reaction until hearing from you all (I don't use a lot of dupixent) and I am certain this tidbit of knowledge will benefit my patients going forward!

Join for free or sign in to see the full answer